Experience of intestinal automicroflora drugs use in patients with functional disorders in the complex therapy of psoriasis vulgaris

The aim was to evaluate the efficacy of intestinal automicroflora medications use in complex therapy in patients with psoriasis vulgaris. The study involved 80 patients with advanced psoriasis vulgaris (mean age 40.5 ± 6.6 years) and 40 dermatologically healthy individuals. The presence and severity of the main intestinal symptoms were determined using the GSRS questionnaire, the quality of life was assessed according to the results of the DLQI dermatological questionnaire, and the severity of psoriasis was determined using the PASI index. The main group of patients with psoriasis vulgaris was divided into two groups depending on the treatment: group I received standard therapy for psoriasis, group II – combined treatment, including standard therapy, correction of microelement status and intestinal automicroflora medications. The results of the study are presented as M ± SD. Statistical data processing, reliability of results at p < 0.05. Results: the average value of the PASI index in patients of the main group was 48.88 ± 9.27 points, according to the DLQI questionnaire – 19.48 ± 6.25 points. According to the GSRS questionnaire, a high prevalence and severity of the main intestinal syndromes in the group of patients with psoriasis vulgaris was established, statistically significant of them – pain, dyspepsia and constipation (p < 0.05). After complex treatment, including standard therapy for the psoriasis vulgaris treatment, correction of the microelement status and oral administration of intestinal automicroflora preparations, there was significant decrease in the prevalence and severity of the main gastroenterological syndromes, a decrease in the PASI index (9.55 ± 4.00 points) and improvement quality of life DLQI (8.40 ± 5.24 points), in comparison with the group of patients receiving standard therapy, where the PASI index after treatment was 47.42 ± 11.22 points, the dermatological index of quality of life DLQI was 15.87 ± 3.84 points. The use of automicroflora preparations is highly effective and can be used in the treatment of not only gastroenterological diseases, but also in the complex therapy of psoriasis vulgaris.

1. Bakaeva N. V., Batkaev E. A., Gitinova M. M. Comparative evaluation of the dermatological index of quality of life in patients with chronic inflammatory dermatoses // RMJ. 2018; 8 (II): 68-71. (In Russ.)]

2. Letyaeva O. I., Chvanova K. V. Quality of life of patients with psoriasis in comorbid conditions // Yuzhno-Uralskii medicinskii zhurnal. 2017; 1: 17-26. (In Russ.)]

3. Pashinyan A. G., Dvornikov A. S., Dontsova. Assessment of the quality of life of patients with psoriasis: a review of current research // Lechebnoe delo. 2019; 2: 32-35. DOI: 10.24411/2071-5315-2019-12109. (In Russ.)]

4. Olisova O. Yu., Garanyan L. G. Epidemiology, etiopathogenesis and comorbidity in psoriasis – new facts // Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2017; 20 (4): 214-219. DOI: 10.18821/1560-9588-2017-20-4-214-219. (In Russ.)]

5. Prokhorov D. V., Ngema M. V., Vintserskaya G. A., etc. The quality of life of patients with severe psoriasis who received combined inpatient treatment (PUVA therapy and methotrexate) // Krymskii terapevticheskii zhurnal. 2020; 1: 78-81. (In Russ.)]

6. Pritulo O. A., Rychkova I. V. A new era in the therapy of psoriasis // Tavricheskii medikobiologicheskii vestnik. 2017; 20 (2): 227-236. (In Russ.)]

7. Eppinga H., Konstantinov S. R., Peppelenbosch M. P., et al. The microbiome and psoriatic arthritis // Curr Rheumatol Rep. 2014; 3 (16): 407. DOI: 10.1007/s11926-013-0407-2.

8. Ghaisas S., Maher J., Kanthasamy A. Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases // Pharmacol Ther. 2016; 158: 52-62. DOI: 10.1016/j.pharmthera.2015.11.012.

9. Karpeeva Yu. S., Novikova V. P., Khavkin A. I., et al. Microbiota and human diseases: possibilities of dietary correction // Rossiiskii vestnik perinatologii i pediatrii. 2020; 65 (5): 116-125. DOI: 10.21508/1027-4065-2020-65-5-116-125. (In Russ.)]

10. Lila A. M., Galushko E. A., Gordeev A. V. and others. The role of the microbiome in the pathogenesis of immuno-inflammatory diseases (debatable issues) // Sovremennaya revmatologiya. 2021; 15 (1): 15-19. DOI: 10.14412/1996-7012-2021-1-15-19. (In Russ.)]

11. Nikolaeva A. A., Shishkin A. N. Features of the intestinal microbiota in psoriasis and psoriatic arthritis// Zdorovie – osnova chelovecheskogo potenciala: problemy i puti ikh resheniya. 2021; 16 (2): 457-463. (In Russ.)]

12. Goncharov A. A., Dolgikh O. V. Immunological and genetic features of the pathogenetic association of psoriasis and dysbiosis of the large intestine // Infektsiya i immunitet. 2021; 11 (2): 237-248. DOI: 10.15789/2220-7619-IAG-1277. (In Russ.)]

13. Kruglova L. S., Lvov A. N., Kagramanova A. V., et al. Psoriasis and inflammatory bowel diseases: pathogenesis and selection of genetically engineered drugs (literature review) // Almanakh klinicheskoi meditsiny. 2019; 47 (6): 568-578. DOI: 10.18786/2072-05-2019-47-062. (In Russ.)]

14. Sturov N. V., Popov S. V., Zhukov V. A. Modern approaches to correction of intestinal microbiota // Meditsinkii sovet. 2021; (4): 136-143. DOI: 10.21518/ 2079-701X-2021-4-136-143. (In Russ.)]

15. Patent 2320355 Russian Federation, IPC A61K 35/74, C12N 1/20, C12R 1/225. Method for obtaining biomass of lactobacillus autostamma liquid "Lacti" / L. E. Chernykh; applicant and patent holder Chernykh L. E. No. 2006122146/13; application 20.06.2006; publ. 27.03.2008, Bul. No. 9. p. 5. (In Russ.)]

16. Nesterov A. S., Gumayunova N. G., Potaturkina-Nesterova N. I., et al. Pathogenetically significant changes in the colonic microflora in psoriasis // Ulyanovskii mediko-biologicheskii zhurnal. 2016; 1: 80-87. (In Russ.)]

17. Gurbo O. P., Frolova O. I., Kovkova G. Yu., et al. The effect of automicroflora preparations and the state of trace element status on the course of psoriasis in patients with functional bowel disorders/ / Meditsinskaya nauka i obrazovanie Urala. 2022; 2 (110): 12-15. DOI: 10.36361/18148999_2022_23_2_12. (In Russ.)]

18. Bakulina N. V., Tikhonov S. V., Ermolenko E. I., et al. The use of E. faecium probiotic and autoprobiotic in patients with type 2 diabetes mellitus// Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I. I. Mechnikova. 2022; 14 (1): 77-88. DOI: 10.17816/mechnikov104795. (In Russ.)]

19. Chicherin I. Yu., Pogorelsky I. P., Lundovskikh I. A. and others. Autoprobiotic therapy // Zhurnal Infectologii. 2013; 5 (4): 43-54. (In Russ.)]

20. Khryanin A. A., Osipenko M. F., Nemchaninova O. B., etc. Strategies for restoring the intestinal mucosal barrier // Eksperimentalnaya i klinicheskaya gastroenterologiya. 2021; 190 (6): 88-95. DOI: 10.31146/1682-8658ecg-190-6-88-95. (In Russ.)]